Q-linea AB (CHIX:QLINES) Other Current Receivables: kr39.07 Mil (As of Mar. 2026)


CHIX:QLINES Q-linea AB CHIX:QLINES
67 GF Score
Price kr1,610.00
GF Value kr1,981.69
! 3 Warning Signs
View Full Analysis

What is Q-linea AB Other Current Receivables?

Q-linea AB CHIX:QLINES 67 Other Current Receivables is kr39.07 Mil as of Mar. 2026. GuruFocus rates CHIX:QLINES with a GF Score™ of 67/100 and a GF Value™ of kr1,981.69. The stock has 3 warning signs investors should review.

Q-linea AB's Other Current Receivables for the quarter that ended in Mar. 2026 was kr39.07 Mil.

Q-linea AB's quarterly Other Current Receivables declined from Sep. 2025 (kr37.42 Mil) to Dec. 2025 (kr0.10 Mil) but then increased from Dec. 2025 (kr0.10 Mil) to Mar. 2026 (kr39.07 Mil).

Q-linea AB's annual Other Current Receivables declined from Dec. 2023 (kr0.54 Mil) to Dec. 2024 (kr0.44 Mil) and declined from Dec. 2024 (kr0.44 Mil) to Dec. 2025 (kr0.10 Mil).

Q-linea AB Other Current Receivables Related Terms

Q-linea AB Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Q-linea AB's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q-linea AB Other Current Receivables Chart

Q-linea AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.14 0.60 0.54 0.44 0.10

Q-linea AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.38 41.13 37.42 0.10 39.07
CHIX:QLINES
67GF Score
Q-linea AB CHIX:QLINES
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q-linea AB Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of kr39.07 Mil mean?
Q-linea AB (CHIX:QLINES) has a Other Current Receivables of kr39.07 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Q-linea AB and its competitors.
Is Q-linea AB's Other Current Receivables too high?
Q-linea AB's current Other Current Receivables is kr39.07 Mil. Overall, Q-linea AB has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's Other Current Receivables compare to ABT and SYK?
Q-linea AB's Other Current Receivables of kr39.07 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Devices & Instruments company?
A good Other Current Receivables depends on the Medical Devices & Instruments industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Q-linea AB and its competitors. Q-linea AB's current Other Current Receivables is kr39.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (CHIX:QLINES) has a current Other Current Receivables of kr39.07 Mil. The stock's GF Value™ is kr1,981.69, compared to a current price of kr1,610.00 — trading 18.8% below its estimated fair value. The current Other Current Receivables is kr39.07 Mil. Q-linea AB's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Q-linea AB (CHIX:QLINES), the current Other Current Receivables is kr39.07 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Q-linea AB (CHIX:QLINES) Overvalued in 2026?

Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued. The current stock price of kr1,610.00 is trading 18.8% below its estimated GF Value™ of kr1,981.69.

Key valuation signals for CHIX:QLINES:

  • Other Current Receivables: kr39.07 Mil
  • GF Value™: kr1,981.69 vs. price of kr1,610.00 (18.8% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the CHIX:QLINES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Q-linea AB Business Description

Other Exchanges QLINEA:Sweden3F80:Germany
Address Dag Hammarskjolds vag 52 A, Uppsala, SWE, SE-752 37
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
67GF Score

Get the complete analysis for CHIX:QLINES

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1,610.00
Price
kr1,981.69
GF Value